Allergan (AGN) to Present IBS Portfolio Data at ACG Annual Meeting
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
Allergan Demonstrates Continued Commitment to Irritable Bowel Syndrome with Diarrhea Management with Two Poster Presentations at ACG 2016
October 14, 2016 8:00 AM EDTDUBLIN, Oct. 14, 2016 /PRNewswire/ --Â Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to the research and development of new treatments for gastrointestinal diseases, today announced that new data from its irritable bowel syndrome portfolio will be featured in two poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas, NV, October 14-19, 2016.Â
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
The scheduled... More